Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is back in the market’s spotlight on December 18, 2025, after a sharp move higher driven by fresh Wall Street optimism and a growing pile of real-world “proof points” for the company’s AI-driven drug discovery thesis. The setup is classic biotech: a clinical readout starts the spark, an analyst upgrade adds oxygen, and the stock begins to trade more on “what this could become” than “what this is today.” On the tape, RXRX has recently traded around $4.68 with a market cap near $2.1 billion, following a double-digit percentage jump in the prior session. Investing.com